Free Trial
→ $100 Trillion “AI Metal” Found in American Ghost Town (From Brownstone Research) (Ad)tc pixel Free NVS Stock Alerts

Novartis (NVS) Stock Forecast & Price Target

Novartis logo
$122.44 -0.34 (-0.28%)
Closing price 03:59 PM Eastern
Extended Trading
$123.62 +1.18 (+0.96%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare

Novartis - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Hold
Based on 9 Analyst Ratings
Sell
3
Hold
4
Buy
2

Based on 9 Wall Street analysts who have issued ratings for Novartis in the last 12 months, the stock has a consensus rating of "Hold." Out of the 9 analysts, 3 have given a sell rating, 4 have given a hold rating, 1 has given a buy rating, and 1 has given a strong buy rating for NVS.

Consensus Price Target

$120.33
-1.72% Downside
According to the 9 analysts' twelve-month price targets for Novartis, the average price target is $120.33. The highest price target for NVS is $123.00, while the lowest price target for NVS is $118.00. The average price target represents a forecasted downside of -1.72% from the current price of $122.44.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for NVS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Novartis and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NVS Analyst Ratings Over Time

TypeCurrent Forecast
9/17/24 to 9/17/25		1 Month Ago
8/18/24 to 8/18/25		3 Months Ago
6/19/24 to 6/19/25		1 Year Ago
9/18/23 to 9/17/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
0 Buy rating(s)
Hold
4 Hold rating(s)
7 Hold rating(s)
6 Hold rating(s)
7 Hold rating(s)
Sell
3 Sell rating(s)
2 Sell rating(s)
3 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$120.33$123.50$123.38$120.70
Forecasted Upside-1.72% Downside-0.37% Downside6.38% Upside4.32% Upside
Consensus RatingHoldHoldHoldReduce

NVS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Novartis Stock vs. The Competition

TypeNovartisMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.78
2.53
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside-1.70% Downside18,475.31% Upside10.99% Upside
News Sentiment Rating
Positive News

See Recent NVS News
Positive News
Positive News
Export to Excel
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
9/12/2025The Goldman Sachs Group
3 of 5 stars
James Quigley
Not Rated
Reiterated RatingNeutral ➝ Sell$119.00 ➝ $118.00-7.54%
8/21/2025Deutsche Bank Aktiengesellschaft
3 of 5 stars		 Reiterated RatingBuy
8/8/2025Morgan Stanley
3 of 5 stars		 UpgradeUnderweight ➝ Equal Weight$123.00+6.14%
4/15/2025BNP Paribas
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
P. Verdult
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
UpgradeStrong-Buy
2/13/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Matthew Weston
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
2/3/2025Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Reiterated RatingUnderweight
12/4/2024HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 DowngradeHold ➝ Reduce
11/19/2024Erste Group Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Reiterated RatingBuy ➝ Hold
10/30/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Boost TargetMarket Perform$118.00 ➝ $120.00+8.53%
9/11/2024Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 DowngradeBuy ➝ Neutral$135.00 ➝ $130.00+11.08%
9/3/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 DowngradeBuy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 08:26 PM ET.


Should I Buy Novartis Stock? NVS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, September 17, 2025. Please send any questions or comments about these Novartis pros and cons to contact@marketbeat.com.

Novartis
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Novartis AG:

  • The current stock price is around $124, reflecting a stable market position and potential for growth.
  • Novartis AG reported a significant increase in quarterly revenue, indicating strong demand for its healthcare products.
  • The company has a solid net margin, showcasing effective cost management and profitability.
  • Analysts have given a consensus rating of "Hold," suggesting that the stock is viewed as a stable investment with potential for appreciation.
  • Recent upgrades from major financial institutions indicate growing confidence in Novartis AG's future performance.

Novartis
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Novartis AG for these reasons:

  • Some analysts have issued "Sell" ratings, indicating concerns about potential declines in stock performance.
  • The stock has experienced fluctuations, with a recent drop of about 2.8%, which may signal volatility.
  • Despite strong revenue growth, the company faces increasing competition in the pharmaceutical sector, which could impact future earnings.
  • Institutional ownership is relatively low, which may suggest a lack of confidence among larger investors.
  • Market conditions and regulatory challenges in the healthcare industry could pose risks to Novartis AG's growth trajectory.

NVS Forecast - Frequently Asked Questions

According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Novartis is $120.33, with a high forecast of $123.00 and a low forecast of $118.00.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 3 sell ratings, 4 hold ratings, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" NVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVS, but not buy additional shares or sell existing shares.

According to analysts, Novartis's stock has a predicted downside of -1.72% based on their 12-month stock forecasts.

Over the previous 90 days, Novartis's stock had 1 upgrade by analysts.

Novartis has been rated by research analysts at Deutsche Bank Aktiengesellschaft, Morgan Stanley, and The Goldman Sachs Group in the past 90 days.

Analysts like Novartis less than other "medical" companies. The consensus rating for Novartis is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how NVS compares to other companies.

Related Companies
Today's Ratings
Top-Rated Stocks
More Ratings Tools

This page (NYSE:NVS) was last updated on 9/17/2025 by MarketBeat.com Staff
From Our Partners
He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...
The Oxford Club | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
Strange crypto pattern discovered by 40-person research team
Something unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...
Crypto Swap Profits | Sponsoredtc pixel
Why Trump’s “Smart Dollar” could rewrite the rules
MUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...
Stansberry Research | Sponsoredtc pixel
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsoredtc pixel
Forget AI Stocks — This Device Will REPLACE the Microchip
While everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...
Banyan Hill Publishing | Sponsoredtc pixel
IRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?
On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...
American Alternative | Sponsoredtc pixel
Forget NVDA. Put $1,000 into this stock now
A massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...
Chaikin Analytics | Sponsoredtc pixel